Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H31N9O15P2.2Na |
| Molecular Weight | 829.5134 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].CC1=C(C)C=C2N(C[C@H](O)[C@H](O)[C@H](O)COP([O-])(=O)OP([O-])(=O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)N4C=NC5=C(N)N=CN=C45)C6=NC(=O)NC(=O)C6=NC2=C1
InChI
InChIKey=XLRHXNIVIZZOON-WFUPGROFSA-L
InChI=1S/C27H33N9O15P2.2Na/c1-10-3-12-13(4-11(10)2)35(24-18(32-12)25(42)34-27(43)33-24)5-14(37)19(39)15(38)6-48-52(44,45)51-53(46,47)49-7-16-20(40)21(41)26(50-16)36-9-31-17-22(28)29-8-30-23(17)36;;/h3-4,8-9,14-16,19-21,26,37-41H,5-7H2,1-2H3,(H,44,45)(H,46,47)(H2,28,29,30)(H,34,42,43);;/q;2*+1/p-2/t14-,15+,16+,19-,20+,21+,26+;;/m0../s1
| Molecular Formula | C27H31N9O15P2 |
| Molecular Weight | 783.5339 |
| Charge | -2 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.wikidoc.org/index.php/FAD
http://www.drugbank.ca/drugs/DB03147
Curator's Comment: description was created based on several sources, including:
http://www.wikidoc.org/index.php/FAD
http://www.drugbank.ca/drugs/DB03147
Flavin adenine dinucleotide is a coenzyme form of vitamin B2. Many oxidoreductases, called flavoenzymes or flavoproteins, require FAD as a prosthetic group, which functions in electron transfers. It is usually used for the prevention and treatment of various diseases that are caused by Vitamin B2 deficiency or metabolic disorder including stomatitis, eczema, etc. No adverse reactions were reported.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Flavitan Approved UseIt is usually used for the prevention and treatment of various diseases that are caused by Vitamin B2 deficiency Launch Date1966 |
|||
| Palliative | Flavitan Approved UseIt is an effective in conjunctivitis treatment. Launch Date1966 |
|||
| Palliative | Flavitan Approved UseIt is usually used for the prevention and treatment of metabolic disorder including stomatitis. Launch Date1966 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Mechanism of chlorpromazine-induced arrhythmia -- arrhythmia and mitochondrial dysfunction. | 1981 Jul |
|
| ACP1GUA-1--a low-activity variant of human erythrocyte acid phosphatase: association with increased glutathione reductase activity. | 1982 May |
|
| Quantification of riboflavin, riboflavin 5'-phosphate and flavin adenine dinucleotide in plasma and urine by high-performance liquid chromatography. | 1987 Dec 25 |
|
| Riboflavin metabolism in the hypothyroid human adult. | 1987 Feb |
|
| Riboflavin metabolism in the hypothyroid newborn. | 1988 Mar |
|
| Nutritional status in anorexia nervosa: clinical chemistry, vitamins, iron and zinc. | 1988 Nov |
|
| [Comparison of biochemical criteria for supplying the human body with riboflavin]. | 1991 Sep-Oct |
|
| Flavin adenine dinucleotide levels in erythrocytes of very low birthweight infants under vitamin supplementation. | 1993 |
|
| Determination of riboflavin and flavocoenzymes in human blood plasma by high-performance liquid chromatography. | 1995 |
|
| Structure of fumarate reductase from Wolinella succinogenes at 2.2 A resolution. | 1999 Nov 25 |
|
| Identification and functional characterization of rat riboflavin transporter 2. | 2009 Apr |
|
| Involvement of riboflavin kinase expression in cellular sensitivity against cisplatin. | 2011 Apr |
Patents
Sample Use Guides
Oral: Take 5 to 45 mg of flavin adenine dinucleotide per day in 1 to 3 divided doses.
Injection: 40 mg one or two times per day
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:30:19 GMT 2023
by
admin
on
Sat Dec 16 09:30:19 GMT 2023
|
| Record UNII |
67U7UHJ04C
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID0046723
Created by
admin on Sat Dec 16 09:30:19 GMT 2023 , Edited by admin on Sat Dec 16 09:30:19 GMT 2023
|
PRIMARY | |||
|
100000078480
Created by
admin on Sat Dec 16 09:30:19 GMT 2023 , Edited by admin on Sat Dec 16 09:30:19 GMT 2023
|
PRIMARY | |||
|
67U7UHJ04C
Created by
admin on Sat Dec 16 09:30:19 GMT 2023 , Edited by admin on Sat Dec 16 09:30:19 GMT 2023
|
PRIMARY | |||
|
DBSALT000903
Created by
admin on Sat Dec 16 09:30:19 GMT 2023 , Edited by admin on Sat Dec 16 09:30:19 GMT 2023
|
PRIMARY | |||
|
84366-81-4
Created by
admin on Sat Dec 16 09:30:19 GMT 2023 , Edited by admin on Sat Dec 16 09:30:19 GMT 2023
|
PRIMARY | |||
|
2734019
Created by
admin on Sat Dec 16 09:30:19 GMT 2023 , Edited by admin on Sat Dec 16 09:30:19 GMT 2023
|
PRIMARY | |||
|
SUB13893MIG
Created by
admin on Sat Dec 16 09:30:19 GMT 2023 , Edited by admin on Sat Dec 16 09:30:19 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |